# DESCRIPTION

- incorporate sequence listing

## FIELD OF THE INVENTION

- relate to composition for raising immune response against coronavirus infection

## BACKGROUND

- introduce poxvirus family
- describe Chordopoxvirinae subfamily
- mention Orthopoxviridae and Avipoxviridae genera
- discuss use of recombinant vaccinia-based viruses as vaccine vectors
- describe poxvirus life cycle
- introduce host range factors
- review host range genes
- discuss vaccinia strains used as smallpox vaccines
- introduce Modified Vaccinia Ankara (MVA)
- describe MVA development
- discuss MVA as a vector for heterologous molecules
- introduce Sementis Copenhagen Vaccinia (SCV) vaccinia virus vector
- describe SCV advantages
- introduce coronaviruses
- describe coronavirus structure
- discuss coronavirus life cycle
- introduce human coronaviruses
- discuss SARS-CoV and MERS-CoV
- introduce COVID-19 pandemic
- discuss SARS-CoV-2 characteristics
- describe SARS-CoV-2 transmission
- discuss SARS-CoV-2 reproductive number
- introduce SARS-CoV-2 spike protein
- describe SARS-CoV-2 spike protein structure
- discuss SARS-CoV-2 spike protein function
- introduce SARS-CoV-2 membrane protein
- describe SARS-CoV-2 membrane protein function
- introduce SARS-CoV-2 envelope protein
- describe SARS-CoV-2 envelope protein function
- introduce SARS-CoV-2 nucleocapsid protein
- describe SARS-CoV-2 nucleocapsid protein function
- discuss SARS-CoV-2 evolution
- introduce SARS-CoV-2 mutations
- discuss SARS-CoV-2 variants
- introduce neutralizing antibodies
- discuss T cell immunity
- introduce CD4 and CD8 T cells
- discuss Th1 polarized CD4 T cells
- introduce T follicular helper cells
- discuss germinal center responses
- introduce humoral immune responses
- discuss Th1-biased response
- introduce antibody-dependent enhancement of disease
- discuss vaccine development
- introduce antigenic sequences
- discuss immunogenicity of spike protein
- discuss immunogenicity of membrane protein
- discuss immunogenicity of nucleocapsid protein
- discuss immunogenicity of envelope protein

## SUMMARY

- introduce SARS-CoV-2 infection prevention composition
- describe attenuated poxvirus with SARS-CoV-2 spike protein
- describe attenuated poxvirus with SARS-CoV-2 membrane protein
- describe attenuated poxvirus with SARS-CoV-2 nucleocapsid protein
- describe attenuated poxvirus with SARS-CoV-2 envelope protein
- provide first aspect of invention: composition with attenuated poxvirus
- provide second aspect of invention: composition with attenuated poxvirus
- provide third aspect of invention: composition with attenuated poxvirus
- provide fourth aspect of invention: composition with attenuated poxvirus
- provide fifth aspect of invention: composition with attenuated poxvirus
- provide sixth aspect of invention: composition with attenuated poxvirus
- provide seventh aspect of invention: composition with attenuated poxvirus
- provide eighth aspect of invention: composition with attenuated poxvirus
- provide ninth aspect of invention: composition with attenuated poxvirus
- provide tenth aspect of invention: composition with attenuated poxvirus
- provide eleventh aspect of invention: composition with attenuated poxvirus
- provide twelfth aspect of invention: composition with attenuated poxvirus
- provide thirteenth aspect of invention: composition with attenuated poxvirus
- provide fourteenth aspect of invention: method of inducing immune response
- provide fifteenth aspect of invention: method of inducing immune response
- provide sixteenth aspect of invention: method of inducing immune response
- provide seventeenth aspect of invention: composition resembling SARS-CoV-2 virus-like particles
- provide eighteenth aspect of invention: composition against coronaviruses with genetic similarity
- provide nineteenth aspect of invention: use of composition in medicament preparation
- describe genetically engineered attenuated vaccinia virus
- describe composition with attenuated vaccinia virus and SARS-CoV-2 spike protein
- describe composition with attenuated vaccinia virus and SARS-CoV-2 membrane protein
- describe composition with attenuated vaccinia virus and SARS-CoV-2 nucleocapsid protein
- describe composition with attenuated vaccinia virus and multiple SARS-CoV-2 proteins
- define composition
- describe nucleic acid sequence encoding SARS-CoV-2 polypeptide
- describe insertion into deleted ORFs of immune modulatory genes
- describe insertion into intergenic region of attenuated vaccinia virus genome
- describe deletion of one or more genes
- describe insertion into deletion site of genes
- describe expression cassette encoding SARS-CoV-2 polypeptide
- describe multiple expression cassettes
- describe composition comprising pharmaceutically acceptable carrier
- describe composition for raising immune response
- describe genetically engineered attenuated vaccinia virus vector
- describe method for preventing SARS-CoV-2 infection
- describe immune response against SARS-CoV-2 antigens
- describe use of composition in medicament preparation
- describe alternative composition
- describe alternative insertion site
- describe alternative gene deletion
- describe alternative expression cassette
- describe alternative composition for raising immune response
- describe alternative genetically engineered attenuated vaccinia virus vector
- describe alternative method for preventing SARS-CoV-2 infection

## DETAILED DESCRIPTION

- define terminology
- introduce materials and methods
- provide references for practitioners
- define preferred methods and materials
- define "comprise" and "consisting of"
- define "consisting essentially of"
- clarify singular and plural forms
- define "and/or"
- define "attenuation" and "attenuated"
- define "control element" and "control sequence"
- define "corresponds to" and "corresponding to"
- define "effective amount"
- define "encode" and "encoding"
- define "endogenous"
- define "expressible" and "expressed"
- define "gene"
- define "heterologous nucleic acid sequence"
- define "heterologous polypeptide"
- describe embodiment of heterologous DNA sequence
- describe embodiment of heterologous DNA sequence with multiple coding sequences
- describe embodiment of heterologous DNA sequence with SARS-CoV-2 genes
- define "protective immune response"
- define "neutralizing antibody response"
- describe inducing an immune response
- describe propagating pox virus vector in mammalian cells
- define homologous recombination and viral propagation
- describe BC19A-12 cell line
- describe SD07-1 cell line
- define "operably connected" and "operably linked"
- define "open reading frame" and "ORF"
- define "polynucleotide" and related terms
- define "polypeptide" and related terms
- define "recombinant" as applied to nucleic acid molecules
- define "sequence identity"
- define "signal sequence" and "signal peptide"
- define "similarity"
- describe optimal alignment of sequences
- define "subject", "patient", "host", and "individual"
- define "transgene"
- define "treatment", "treating", and related terms
- define "wild-type", "natural", "native", and related terms
- define "viral infection"
- define "virus-like particles" or "VLP"
- define "variants"
- describe nucleic acid sequence identity
- describe amino acid sequence identity
- define "hybridize under stringent conditions"
- define "deletion"
- define "gene"
- define "regulatory element" and "regulatory sequence"
- describe chimeric constructs
- describe promoters
- describe constitutive and inducible promoters
- describe viral promoters
- describe poxviral promoter types
- describe early/late promoters
- describe compact, synthetic promoters
- describe native early/late promoters
- describe enhancer elements
- describe SV40 early gene enhancer
- describe Rous Sarcoma Virus LTR enhancer/promoter
- describe human CMV enhancer elements
- describe CMV intron A sequence
- conclude definitions
- define 3' non-translated sequence
- describe polyadenylation signal
- describe selectable marker gene
- describe expression of poxvirus structural gene
- describe promoters
- introduce SARS-CoV-2
- describe SARS-CoV-2 genome
- describe SARS-CoV-2 variants
- describe S1 subunit of spike protein
- describe immunodominant T cell epitopes
- describe genetic sequence of SARS-CoV-2
- introduce attenuated poxvirus
- describe attenuation of poxvirus
- describe poxvirus family
- describe Orthopoxviridae
- describe Avipoxviridae
- describe poxvirus as vectors
- describe vaccinia virus
- describe suitable attenuated poxviruses
- describe Sementis Copenhagen Vector
- describe modification of poxvirus
- describe deletion of essential assembly gene
- describe deletion of immunomodulatory gene
- describe insertion of heterologous DNA sequence
- describe intergenic regions for insertion
- describe old nomenclature for ORFs
- describe modification of vaccinia virus
- describe deletion of A41L gene
- describe deletion of A41L and D13L genes
- describe deletion of A41L, D13L, and 87R-B8R genes
- describe deletion of A41L, D13L, 87R-B8R, C3L, and A39R genes
- describe advantages of deletion
- describe insertion of heterologous DNA sequence in intergenic region
- introduce SCV vector
- express structural and non-structural proteins
- assemble into VLPs
- generate immune response
- provide long-lasting immune response
- describe composition for raising immune response
- modify poxvirus genome
- encode spike polypeptide
- encode membrane polypeptide
- encode nucleocapsid polypeptide
- describe engineered spike protein variants
- provide composition for raising immune response
- modify poxvirus genome
- encode S1 receptor-binding domain
- provide composition for raising immune response
- modify poxvirus genome
- encode multiple polypeptides
- provide composition for raising immune response
- modify poxvirus genome
- encode multiple polypeptides
- provide method of inducing immune response
- administer composition
- provide method of inducing immune response
- administer mixed composition
- provide method of inducing immune response
- administer mixed composition
- describe immunogenicity of spike protein
- describe immunogenicity of membrane protein
- describe immunogenicity of nucleocapsid protein
- describe immunogenicity of combined proteins
- describe VLP formation
- describe preferred attenuated poxvirus
- describe modified orthopoxvirus
- describe deletion of D13L and K1L genes
- provide non-limiting examples

### Construction of Vaccines

- construct SCV-COVID19 vaccines
- remove early transcription termination signals
- synthesize expression cassettes for antigenic transgenes
- include control elements and endonuclease recognition sites
- show specific examples of expression cassettes
- insert transgene expression cassettes into HR plasmids
- describe HR plasmid components
- show specific examples of HR cassettes
- prepare HR plasmid for virus construction
- perform homologous recombination
- infect cells with SCV-SMX06
- transfect cells with Not I digested HR plasmid
- incubate cells until fluorescent cells appear
- purify recombinant virus from parent virus
- remove selection genes via intramolecular recombination
- enrich and purify virus without selection markers
- validate virus seed stocks by PCR and DNA sequencing
- validate virus seed stocks by western blot or immunostaining
- summarize construction strategies
- describe SCV derivation from Copenhagen strain
- describe SCV-SMX06 derivation from SCV
- illustrate gene deletions in SCV-SMX06
- describe transgene insertion into deletion sites
- describe variations of SCV-COVID19 vaccines
- describe recombinant virus SCV-COVID19A construction
- describe recombinant virus SCV-COVID19B construction
- describe recombinant virus SCV-COVID19C construction
- describe recombinant virus SCV-COVID19D construction
- describe recombinant virus SCV-COVID19E construction
- describe recombinant virus SCV-COVID19F construction
- describe recombinant virus SCV-COVID19G construction
- describe recombinant virus SCV-COVID19H construction
- describe recombinant virus SCV-COVID19I construction

### Example 2

- describe experimental strategy
- vaccinate mice with SCV-COVID19D or vector control
- obtain blood samples before and after vaccination
- determine S1-specific IgG levels and neutralizing antibody levels
- perform virus neutralization test
- perform enzyme-linked immunosorbent assay for mouse sera
- present results of neutralizing antibody titres and IgG subclass profiling

### Example 3

- define T cell response
- experimental strategy
- ELISpot assay
- intracellular cytokine staining analysis
- results

### Conclusion

- summarize results

### Example 4

- experimental strategy
- western blot
- enzyme-linked immunosorbent assay
- results
- western blot results
- ELISA results
- conclusion

### Example 5

- experimental strategy
- enzyme-linked immunosorbent assay
- cPass SARS-CoV-2 neutralization antibody detection
- results
- S1-specific IgG levels
- neutralizing antibody levels
- comparison of inbred and outbred mice
- results interpretation
- conclusion

### Example 6

- experimental strategy
- method
- CD8 and CD4 T cell responses
- intracellular cytokine staining
- peptide pools
- results
- spike-specific triple-cytokine-positive CD8 T cell response
- spike-specific granzyme-B-producing CD8 T cell response
- spike-specific IFN-γ-producing CD4 T cell response

### Example 7

- introduce pre-existing immunity issue
- motivate orthopoxvirus-based vaccines
- describe experimental strategy
- outline treatment groups
- describe method
- present results
- analyze antibody response
- discuss neutralizing antibody levels
- introduce prime-boost strategy
- describe experimental strategy
- outline treatment groups
- describe method
- present results
- analyze antibody response
- discuss neutralizing antibody levels
- conclude on pre-existing immunity
- introduce aging mice
- describe experimental strategy
- outline treatment groups
- describe method
- present results
- analyze antibody response
- discuss neutralizing antibody levels
- conclude on aging mice
- present example 7
- detect IFN-γ producing T cell responses
- conclude prophylactic protection
- present example 12
- describe experimental strategy
- perform ELISpot assay
- evaluate T cell responses
- present results
- conclude T cell responses
- present example 13
- describe experimental strategy
- perform ELISA and ELISpot assays
- evaluate antibody and T cell responses
- present results
- conclude immune responses
- present example 14
- discuss antigenic competition
- describe experimental strategy
- perform vaccination study
- evaluate immune responses
- present results
- conclude optimal immune responses
- present example 15
- describe experimental strategy
- perform neutralization assay
- evaluate protection
- present results
- conclude protection
- present example 15S
- evaluate cytolytic T lymphocyte activity

